2:41 PM
Mar 12, 2018
 |  BC Extra  |  Financial News

Tissue 3-D printing play OxSyBio unveils £10M series A

OxSyBio Ltd. (London, U.K.) secured £10 million ($13.9 million) in a series A round led by new investor Woodford Investment Management. IP Group, which seeded the company with £1 million ($1.4 million) in 2014, and new investor Parkwalk Advisors also participated.

OxSyBio said part of the round is subject to milestones, but CEO Hadrian Green declined to disclose details.

Green said he expects the funding to give the company about two and a half years of runway.

OxSyBio spun out of the University of Oxford in 2014. The company is developing 3-D printing technology based on droplet networks to print tissues and tissue-like materials for drug testing and regenerative medicine. The method gives precise control over cell locations, which could improve the reproducibility and applicability of information gained from model tissues produced using 3-D cell culture or organ-on-a-chip technologies (see BioCentury, Jan. 19, 2015).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD